The efficacy and safety of Fractional Erbium:YAG assisting percutaneous absorption of triamcinolone acetonide in different dosage forms : A pilot Study
Phase 4
- Conditions
- Healthy human volunteersDrug absorptionFractional Erbium yagSteroid
- Registration Number
- TCTR20230417002
- Lead Sponsor
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
1. Healthy Thai descendant
2. Have healthy skin, i.e., the skin on the forearm is free of inflammation, infection, and dyspigmentation.
3. Patients who voluntarily agree to participate in the study
Exclusion Criteria
1. Being pregnant, breastfeeding, or after giving birth for no more than 3 months
2. Have open wounds, scars, infections or tattoos on the forearm
3. Perform any skin treatment (e.g., tanning, laser) on the forearm within 4 weeks prior to the start of the study.
4. Have a history of allergy to steroids
5. Have photosensitive rash or sensitivity to light
6. Have a history of using substances that affect wound healing, such as using steroids or smoking regularly
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Amount of TA cream/solution in the stripped stratum corneum Immediate after treatment Measure using Ultra-High-Performance Liquid Chromatography
- Secondary Outcome Measures
Name Time Method Adverse events Immediate, 2 weeks after procedure Clinical evaluation